Motexafin gadolinium: a novel radiosensitizer for brain tumors

Bibliography

• Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006;24(8):1295-304
   PubMed Web of Science ®Google Scholar
• CBTRUS. Central Brain Tumor Registry of the United States 2008 statistical report: primary brain tumors in the United States; 2008. Available from: http://www.cbtrus.org/ [Cited 15 August 2008]
   Google Scholar
• Nguyen T, Deangelis LM. Treatment of brain metastases. J Support Oncol 2004;2(5):405-10; discussion 11-6
   PubMedGoogle Scholar
• Tsao MN, Lloyd N, Wong R, et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006;3:CD003869
   PubMedGoogle Scholar
• Patchell RA, Cirrincione C, Thaler HT, et al. Single brain metastases: surgery plus radiation or radiation alone. Neurology 1986;36(4):447-53
   PubMed Web of Science ®Google Scholar
• Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363(9422):1665-72
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280(17):1485-9
   PubMed Web of Science ®Google Scholar
• Iliakis G, Kurtzman S. Application of non-hypoxic cell sensitizers in radiobiology and radiotherapy: rationale and future prospects. Int J Radiat Oncol Biol Phys 1989;16(5):1235-41
   PubMed Web of Science ®Google Scholar
• Forouzannia A, Richards GM, Khuntia D, Mehta MP. Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Rev Anticancer Ther 2007;7(6):785-94
   PubMed Web of Science ®Google Scholar
• Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007;25(26):4066-74
   PubMed Web of Science ®Google Scholar
• Churchill-Davidson I. Hyperbaric oxygen and radiotherapy: general principles and problems. Nunt Radiol 1968;34(1):5-13
   PubMedGoogle Scholar
• Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006;24(1):106-14
   PubMed Web of Science ®Google Scholar
• Scott C, Suh J, Stea B, et al. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol 2007;30(6):580-7
   PubMed Web of Science ®Google Scholar
• McGinn CJ, Lawrence TS. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 2001;11(4):270-80
   PubMed Web of Science ®Google Scholar
• Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 2008;14(21):6744-50
   PubMed Web of Science ®Google Scholar
• Khuntia D, Tome WA, Mehta MP. Radiation techniques in neuro-oncology. Neurother 2009;6(3):487-99
   PubMed Web of Science ®Google Scholar
• Viani GA, Castilho MS, Salvajoli JV, et al. Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems. BMC Cancer 2007;7:53
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
   PubMed Web of Science ®Google Scholar
• Richards GM, Khuntia D, Mehta MP. Therapeutic management of metastatic brain tumors. Crit Rev Oncol Hematol 2007;61(1):70-8
   PubMed Web of Science ®Google Scholar
• Shaw E, Scott C, Suh J, et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the radiation therapy oncology group recursive partitioning analysis brain metastases database. J Clin Oncol 2003;21(12):2364-71
   PubMed Web of Science ®Google Scholar
• Khuntia D, Mehta M. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 2004;4(6):981-9
   PubMedGoogle Scholar
• Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007;5(11):894-902, 7-15
   PubMedGoogle Scholar
• Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001;19(7):2074-83
   PubMed Web of Science ®Google Scholar
• Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 2000;59(7):733-9
   PubMed Web of Science ®Google Scholar
• Magda D, Lecane P, Miller RA, et al. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res 2005;65(9):3837-45
   PubMed Web of Science ®Google Scholar
• Rodrigus P. Motexafin gadolinium: a possible new radiosensitiser. Expert Opin Investig Drugs 2003;12(7):1205-10
   PubMed Web of Science ®Google Scholar
• Magda D, Lepp C, Gerasimchuk N, et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 2001;51(4):1025-36
   PubMed Web of Science ®Google Scholar
• Evans JP, Xu F, Sirisawad M, et al. Motexafin gadolinium-induced cell death correlates with HO1 expression and inhibition of p450 reductase-dependent activities. Mol Pharmacol 2007;71(1):193-200
   PubMed Web of Science ®Google Scholar
• Tonissen KF, Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 2009;53(1):87-103
   PubMed Web of Science ®Google Scholar
• Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 2006;281(16):10691-7
   PubMed Web of Science ®Google Scholar
• Zahedi Avval F, Berndt C, Pramanik A, Holmgren A. Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun 2009;379(3):775-9
   PubMed Web of Science ®Google Scholar
• Avaal FZ, Berndt C, Pramanik A, Holmgren A. Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun 2009;379(3):775-79
   PubMedGoogle Scholar
• Chen J, Ramos J, Sirisawad M, et al. Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis. Apoptosis 2005;10(5):1131-42
   PubMed Web of Science ®Google Scholar
• Evens AM. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol 2004;16(6):576-80
   PubMed Web of Science ®Google Scholar
• Wu GN, Ford JM, Alger JR. MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain. J Neurooncol 2006;77(1):95-103
   PubMed Web of Science ®Google Scholar
• Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;21(13):2529-36
   PubMed Web of Science ®Google Scholar
• Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37(4):745-51
   PubMed Web of Science ®Google Scholar
• Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22(1):157-65
   PubMed Web of Science ®Google Scholar
• Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009;73(4):1069-76
   PubMed Web of Science ®Google Scholar
• Ford JM. A phase I dose escalation trial of motexafin gadolinium as a radiation sensitizer in patients with newly diagnosed glioblastoma multiforme. American Society of Therapeutic Radiation Oncologoy, San Francisco; 2001. p. 205
   Google Scholar
• Suh J, Chang E, Timmerman R, et al. Phase II trial of motexafin gadolinium (MGd, Xcytrin) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol (abstract) 2002;21(13):2108
   Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003
   PubMed Web of Science ®Google Scholar
• Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999;5(4):739-45
   PubMed Web of Science ®Google Scholar
• Bradley KA, Pollack IF, Reid JM, et al. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol 2008;10(5):752-8
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322(8):494-500
   PubMed Web of Science ®Google Scholar
• Amato RJ, Jac J, Hernandez-McClain J. Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results. Clin Genitourin Cancer 2008;6(2):73-8
   PubMedGoogle Scholar